Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-108851
Filing Date
2025-08-14
Accepted
2025-08-14 16:05:09
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9912
  Complete submission text file 0000950170-25-108851.txt   11727
Mailing Address 301 9-19 HACHIYAMA, SHIBUYA TOKYO M0 150-0035
Business Address 301 9-19 HACHIYAMA, SHIBUYA TOKYO M0 150-0035 81 90-3536-3820
Catalys Pacific Fund, LP (Filed by) CIK: 0001746274 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087
Business Address 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087 (888) 378-6240
Mineralys Therapeutics, Inc. (Subject) CIK: 0001933414 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94000 | Film No.: 251218710
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)